Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?

被引:56
作者
Wohlfarth, Kai [2 ]
Sycha, Thomas [3 ]
Ranoux, Daniele [4 ]
Naver, Hans
Caird, David [1 ]
机构
[1] Ipsen Pharm GmbH, D-76275 Ettlingen, Germany
[2] BG Kliniken Bergmannstrost, Dept Neurol, Halle S, Germany
[3] Med Univ Vienna, Dept Neurol, Vienna, Austria
[4] Hop Limoges, Dept Neurol, Limoges, France
关键词
TOXIN TYPE-A; DOUBLE-BLIND; RESPECTIVE POTENCIES; CERVICAL DYSTONIA; DYSPORT; BOTOX; FORMULATIONS; EFFICACY; SAFETY; PHARMACOLOGY;
D O I
10.1185/03007990903028203
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: The units of different preparations of botulinum neurotoxin type A (BoNT-A) have different potencies, and dosing recommendations for each product are not interchangeable. Historically, there has been debate concerning the dose-equivalence ratio that should be used in clinical practice. Methods: Published evidence was considered to establish an appropriate dose-conversion ratio for the two main commercially available preparations of BoNT-A-Dysport (Dp) and Botox (Bx). Results: Four key areas of evidence were identified: nonclinical and preclinical studies; studies exploring the diffusion characteristics and effects of complexing proteins; comparative experimental data from human studies; and clinical studies. Nonclinical data indicate that the principal reasons for differences in unit potency between the two products are dilution artefacts in the mouse assay. Use of saline as a diluent, at high dilutions, results in significant loss of potency in the Bx assay, whereas use of gelatin phosphate buffer in the Dp assay procedure protects the toxin during dilution. The published data on mouse assays show a Dp : Bx unit ratio range of 2.3-2.5 : 1 in saline and 1.8-3.2 : 1 in gelatin phosphate buffer. Data indicate that complexing proteins or size of the complex, which is highly pH sensitive, play no role in toxin diffusion and that Dp and Bx have similar diffusion characteristics when used at comparable doses. Randomized, controlled clinical studies indicate that 3 : 1 is more appropriate than 4 : 1, but the two products are not equivalent at this ratio. Comparative human experimental studies using the extensor digitorum brevis test, facial lines and anhidrotic action halo tests support dose-conversion ratios less than 3 : 1. Limitations: Data comparing dose equivalence ratios from the non-clinical setting should be extrapolated into the clinical setting with some caution. Conclusions: Dose-conversion ratios between Dp and Bx of 4 : 1 and greater are not supported by the recent literature.
引用
收藏
页码:1573 / 1584
页数:12
相关论文
共 50 条
[1]
Preclinical update on BOTOX® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations [J].
Aoki, KR .
EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 :S3-S10
[2]
A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice [J].
Aoki, KR .
TOXICON, 2001, 39 (12) :1815-1820
[3]
A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke [J].
Bakheit, AMO ;
Pittock, S ;
Moore, AP ;
Wurker, M ;
Otto, S ;
Erbguth, F ;
Coxon, L .
EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (06) :559-565
[4]
Botulinum toxins: Potency and antigenic properties [J].
Bigalke, H .
KLINISCHE NEUROPHYSIOLOGIE, 2001, 32 (04) :210-212
[5]
BRIN MF, 1993, J ROY SOC MED, V86, P494
[6]
Botulinum toxin type A: History and current cosmetic use in the upper face [J].
Carruthers, A ;
Carruthers, J .
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2001, 20 (02) :71-84
[7]
CLARKE M, 2002, COCHRANE REV HDB 4 1
[8]
Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis [J].
De Almeida, Ada R. Trindade ;
Marques, Elisa ;
De Almeida, Janete ;
Cunha, Thais ;
Boraso, Rosana .
DERMATOLOGIC SURGERY, 2007, 33 :S37-S43
[9]
Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions [J].
Eisele, Karl-Heinz ;
Taylor, Harold V. .
TOXICON, 2008, 51 :10-10
[10]
Felber ES, 2006, J AM OSTEOPATH ASSOC, V106, P609